Summary of Product Characteristics

This section provides European Commission approval and labeling information for Entyvio in Ulcerative Colitis and Crohn's Disease.                  

Entyvio Therapeutic Indications


Ulcerative Colitis

Entyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor‑alpha (TNFα) antagonist.

 

Crohns Disease

Entyvio is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor‑alpha (TNFα) antagonist.

.pdfSummary of Product CharacteristicsDownload the European Summary of Product Characteristics for comprehensive clinical, pharmacological and prescribing information about Entyvio.